Announced Wed, 28 Oct, 2026 · 21:04 IST
Q2 revenue up 46.8%, PAT up 249%; Rs 57.46 cr stamp duty case; CFO change
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults RestatedExceptional ItemEmphasis Of MatterResults View source PDFExplain this filing
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Q2 FY27: standalone revenue rose 46.8% to Rs 612.59 cr; standalone PAT Rs 65.75 cr versus Rs 23.50 cr. Consolidated PAT Rs 71.47 cr versus Rs 20.49 cr (+249%); H1 PAT Rs 147.61 cr (+122%). Stamp duty Rs 25 cr plus Rs 34.5 cr penalties: Rs 2.04 cr booked as exceptional item, Rs 57.46 cr contingent liability; court case pending. FY26 figures restated. CFO Piyush Lakhani resigns Oct 30; Vibha Thakkar starts Oct 31.
Likely market impact
Strong profit growth is positive, but the Rs 57.46 cr stamp duty exposure, pending court case and CFO change add risk.